Optimising Orphan Drug Development

Optimising Orphan Drug Development

Tailor a specific approach for orphan drug product development across various rare disease classifications and optimise the commercial aspects

15-16 Nov 2010: Brussels, Belgium

10 years on since the introduction of the EU Orphan Medicinal Products Regulation policy makers are reviewing these with a time limit until 2013 so we will be examining the regulatory landscape and the possible changes, but also the changes in reimbursement criteria and how this will impact upon orphan drugs is of major importance.

This inaugural marcus evans conference will be focusing on how to develop orphan drug products for various rare disease classifications and how to market these drugs to gain access in new geographical markets. We will also be discussing how to overcome these developmental challenges and the opportunities available for further progress and diversification.